Endothelin receptor antagonist reduces markers of PCa

Chicago-The selective endothelin receptor antagonist atrasentan significantly attenuates changes in biochemical markers of bone metabolism and disease progression in a group of patients with advanced hormone-refractory prostate cancer that had progressed on placebo, according to the results of a randomized clinical trial.

Related Content:

Drug TherapyFemale Urology

Dr. Kate Kraft discusses her path to urology

Sexual function significantly improved after single incision sling for SUI

Pivotal data for lumasiran in PH1 published in NEJM